Project Details
Outline of Final Research Achievements
The anti-herpetic effect of ASP2151, a novel helicase-primase inhibitor, was compared with acyclovir (ACV). ASP2151 reduced virus release to the culture supernatants as compared with ACV. In addition, the recovery of HSV yields after removal of antiviral drug was significantly more delayed by ASP2151 than by ACV. These results indicated that ASP2151 is more effective in the reducing viral load in the HSV-infected cells than ACV in the condition used in this study.
| Status | Finished |
|---|---|
| Effective start/end date | 2013/08/30 → 2015/03/31 |
Funding
- Japan Society for the Promotion of Science: ¥2,990,000.00
Keywords
- 水痘・帯状疱疹ウイルス
- 単純ヘルペスウイルス
- 帯状疱疹後疼痛
- 帯状疱疹
- 帯状疱疹後神経痛
- 感染症